Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan

A retrospective review of 48 patients with metastatic colorectal cancer

Nozomu Fuse, Toshihiko Doi, Atsushi Ohtsu, Tomonori Yano, Yasuo Hamamoto, Keiko Minashi, Makoto Tahara, Manabu Muto, Masahiro Asaka, Shigeaki Yoshida

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. A combination of irinotecan and infusional fluorouracil/ leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer. The aim of this study was to evaluate the feasibility of FOLFIRI in a Japanese population with metastatic colorectal cancer. Methods. This retrospective analysis included 48 patients with unresectable metastatic colorectal cancer who received FOLFIRI between May 2004 and June 2005. Evaluation points included adverse events, dose intensity, response rate, progression-free survival, and overall survival. Results. Thirty-eight (79%) patients received FOLFIRI as first-line chemotherapy. Eighteen patients received original full-dose FOLFIRI and 30 patients received reduced FOLFIRI with irinotecan at 150mg/m2. Eighteen (38%) of the 48 patients experienced grade 3 or 4 neutropenia, 5 (10%) had grade 3 vomiting and 5 (10%) had grade 3 diarrhea. Toxicity was tolerable, with appropriate dose reduction if necessary. There were no treatment-related deaths or early deaths within the first 60 days of treatment. Median dose intensities (with relative dose intensities in parentheses) in all patients and in patients who received full-dose FOLFIRI were 129mg/m2 per 2 weeks (71%) and 144mg/m 2 per 2 weeks (80%) for irinotecan and 2349mg/m2 per 2 weeks (84%) and 2376mg/m2 per 2 weeks (85%) for fluorouracil, respectively. The response rate in patients with measurable lesions was 37% (13/35; 95% confidence interval [CI], 21.1%-53.2%), and median progression-free survival was 8.4 months (95% CI, 6.4-10.3). Conclusion. The dose intensity of irinotecan was relatively low, and toxicity was tolerable with appropriate dose reduction; efficacy was comparable to that previously reported. FOLFIRI is feasible and can be one of the standard treatment options for Japanese patients with metastatic colorectal cancer.

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume13
Issue number2
DOIs
Publication statusPublished - 2008 Apr 1
Externally publishedYes

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Japan
Safety
Disease-Free Survival
Confidence Intervals
Drug Therapy

Keywords

  • Colorectal cancer
  • Feasibility
  • FOLFIRI
  • Irinotecan
  • Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan : A retrospective review of 48 patients with metastatic colorectal cancer. / Fuse, Nozomu; Doi, Toshihiko; Ohtsu, Atsushi; Yano, Tomonori; Hamamoto, Yasuo; Minashi, Keiko; Tahara, Makoto; Muto, Manabu; Asaka, Masahiro; Yoshida, Shigeaki.

In: International Journal of Clinical Oncology, Vol. 13, No. 2, 01.04.2008, p. 144-149.

Research output: Contribution to journalArticle

Fuse, Nozomu ; Doi, Toshihiko ; Ohtsu, Atsushi ; Yano, Tomonori ; Hamamoto, Yasuo ; Minashi, Keiko ; Tahara, Makoto ; Muto, Manabu ; Asaka, Masahiro ; Yoshida, Shigeaki. / Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan : A retrospective review of 48 patients with metastatic colorectal cancer. In: International Journal of Clinical Oncology. 2008 ; Vol. 13, No. 2. pp. 144-149.
@article{246e738841064abdb3d14c14d47d1584,
title = "Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: A retrospective review of 48 patients with metastatic colorectal cancer",
abstract = "Background. A combination of irinotecan and infusional fluorouracil/ leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer. The aim of this study was to evaluate the feasibility of FOLFIRI in a Japanese population with metastatic colorectal cancer. Methods. This retrospective analysis included 48 patients with unresectable metastatic colorectal cancer who received FOLFIRI between May 2004 and June 2005. Evaluation points included adverse events, dose intensity, response rate, progression-free survival, and overall survival. Results. Thirty-eight (79{\%}) patients received FOLFIRI as first-line chemotherapy. Eighteen patients received original full-dose FOLFIRI and 30 patients received reduced FOLFIRI with irinotecan at 150mg/m2. Eighteen (38{\%}) of the 48 patients experienced grade 3 or 4 neutropenia, 5 (10{\%}) had grade 3 vomiting and 5 (10{\%}) had grade 3 diarrhea. Toxicity was tolerable, with appropriate dose reduction if necessary. There were no treatment-related deaths or early deaths within the first 60 days of treatment. Median dose intensities (with relative dose intensities in parentheses) in all patients and in patients who received full-dose FOLFIRI were 129mg/m2 per 2 weeks (71{\%}) and 144mg/m 2 per 2 weeks (80{\%}) for irinotecan and 2349mg/m2 per 2 weeks (84{\%}) and 2376mg/m2 per 2 weeks (85{\%}) for fluorouracil, respectively. The response rate in patients with measurable lesions was 37{\%} (13/35; 95{\%} confidence interval [CI], 21.1{\%}-53.2{\%}), and median progression-free survival was 8.4 months (95{\%} CI, 6.4-10.3). Conclusion. The dose intensity of irinotecan was relatively low, and toxicity was tolerable with appropriate dose reduction; efficacy was comparable to that previously reported. FOLFIRI is feasible and can be one of the standard treatment options for Japanese patients with metastatic colorectal cancer.",
keywords = "Colorectal cancer, Feasibility, FOLFIRI, Irinotecan, Safety",
author = "Nozomu Fuse and Toshihiko Doi and Atsushi Ohtsu and Tomonori Yano and Yasuo Hamamoto and Keiko Minashi and Makoto Tahara and Manabu Muto and Masahiro Asaka and Shigeaki Yoshida",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s10147-007-0737-z",
language = "English",
volume = "13",
pages = "144--149",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan

T2 - A retrospective review of 48 patients with metastatic colorectal cancer

AU - Fuse, Nozomu

AU - Doi, Toshihiko

AU - Ohtsu, Atsushi

AU - Yano, Tomonori

AU - Hamamoto, Yasuo

AU - Minashi, Keiko

AU - Tahara, Makoto

AU - Muto, Manabu

AU - Asaka, Masahiro

AU - Yoshida, Shigeaki

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background. A combination of irinotecan and infusional fluorouracil/ leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer. The aim of this study was to evaluate the feasibility of FOLFIRI in a Japanese population with metastatic colorectal cancer. Methods. This retrospective analysis included 48 patients with unresectable metastatic colorectal cancer who received FOLFIRI between May 2004 and June 2005. Evaluation points included adverse events, dose intensity, response rate, progression-free survival, and overall survival. Results. Thirty-eight (79%) patients received FOLFIRI as first-line chemotherapy. Eighteen patients received original full-dose FOLFIRI and 30 patients received reduced FOLFIRI with irinotecan at 150mg/m2. Eighteen (38%) of the 48 patients experienced grade 3 or 4 neutropenia, 5 (10%) had grade 3 vomiting and 5 (10%) had grade 3 diarrhea. Toxicity was tolerable, with appropriate dose reduction if necessary. There were no treatment-related deaths or early deaths within the first 60 days of treatment. Median dose intensities (with relative dose intensities in parentheses) in all patients and in patients who received full-dose FOLFIRI were 129mg/m2 per 2 weeks (71%) and 144mg/m 2 per 2 weeks (80%) for irinotecan and 2349mg/m2 per 2 weeks (84%) and 2376mg/m2 per 2 weeks (85%) for fluorouracil, respectively. The response rate in patients with measurable lesions was 37% (13/35; 95% confidence interval [CI], 21.1%-53.2%), and median progression-free survival was 8.4 months (95% CI, 6.4-10.3). Conclusion. The dose intensity of irinotecan was relatively low, and toxicity was tolerable with appropriate dose reduction; efficacy was comparable to that previously reported. FOLFIRI is feasible and can be one of the standard treatment options for Japanese patients with metastatic colorectal cancer.

AB - Background. A combination of irinotecan and infusional fluorouracil/ leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer. The aim of this study was to evaluate the feasibility of FOLFIRI in a Japanese population with metastatic colorectal cancer. Methods. This retrospective analysis included 48 patients with unresectable metastatic colorectal cancer who received FOLFIRI between May 2004 and June 2005. Evaluation points included adverse events, dose intensity, response rate, progression-free survival, and overall survival. Results. Thirty-eight (79%) patients received FOLFIRI as first-line chemotherapy. Eighteen patients received original full-dose FOLFIRI and 30 patients received reduced FOLFIRI with irinotecan at 150mg/m2. Eighteen (38%) of the 48 patients experienced grade 3 or 4 neutropenia, 5 (10%) had grade 3 vomiting and 5 (10%) had grade 3 diarrhea. Toxicity was tolerable, with appropriate dose reduction if necessary. There were no treatment-related deaths or early deaths within the first 60 days of treatment. Median dose intensities (with relative dose intensities in parentheses) in all patients and in patients who received full-dose FOLFIRI were 129mg/m2 per 2 weeks (71%) and 144mg/m 2 per 2 weeks (80%) for irinotecan and 2349mg/m2 per 2 weeks (84%) and 2376mg/m2 per 2 weeks (85%) for fluorouracil, respectively. The response rate in patients with measurable lesions was 37% (13/35; 95% confidence interval [CI], 21.1%-53.2%), and median progression-free survival was 8.4 months (95% CI, 6.4-10.3). Conclusion. The dose intensity of irinotecan was relatively low, and toxicity was tolerable with appropriate dose reduction; efficacy was comparable to that previously reported. FOLFIRI is feasible and can be one of the standard treatment options for Japanese patients with metastatic colorectal cancer.

KW - Colorectal cancer

KW - Feasibility

KW - FOLFIRI

KW - Irinotecan

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=43449128842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449128842&partnerID=8YFLogxK

U2 - 10.1007/s10147-007-0737-z

DO - 10.1007/s10147-007-0737-z

M3 - Article

VL - 13

SP - 144

EP - 149

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -